Eli Lilly & Co.: PharmaVitae Profile now available at ReportsandReports

Dallas, TX: ReportsandReports announce Eli Lilly & Co.: PharmaVitae Profile Market Research Report in its Store.

Browse complete Report at: http://www.reportsandreports.com/reports/8202-eli-lilly-co-pharmavitae-profile.html

Introduction

This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Eli Lilly's performance against key rivals in the prescription pharmaceutical sector
Assess the commercial outlook for key new launch products Effient and Byetta LAR
Evaluate Eli Lilly's ability to overcome the adverse impact of patent expiry for Zyprexa, Cymbalta and other key franchises over the period 2011-14

Table Of Contents

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Eli Lilly: PharmaVitae forecasts at a glance 8
Strategic insight 9
The looming challenge of 'Years Y and Z' 9
Strategies to weather the loss of sales 10
Investment following 'Year X' 10
Looking to external sources of growth 11
Outlook heavily dependent upon Effient and Byetta LAR 12
Out-sourcing spreads risk and leverages expertise 15
SWOT analysis 16
Strengths 17
Weaknesses 18
Opportunities 19
Threats 21

Table of Contents 22

Table of figures 24

Chapter 3 Quarterly news update 25

Key findings 25
Product developments 26
Deals and alliances 27
Product deals 27
Technology deals 27
M&A activity 27
Company announcements 28
Future product milestones 29

Chapter 4 Company introduction 30

Key findings 30
Background 31
Key corporate developments 31
M&A history 32
Advanced Cardiovascular Systems acquired 32
Hybritech acquired 32
DowElanco formed 33
Devices for Vascular Intervention acquired 33
Origin Medsystems acquired 33
Sphinx Pharmaceuticals acquired 33
Guidant spun-out 33
Remaining medical device businesses divested 33
PCS Health Systems acquired 33
Hybritech divested 34
DowElanco holding sold 34
PCS Health Systems sold 34
Applied Molecular Evolution acquired 34
ICOS acquired 34
Hypnion acquired 34
Ivy Animal Health acquired 34
SGX Pharmaceuticals acquired 34
ImClone Systems acquired 35
M&A strategy 35
Current corporate structure 36
Pharmaceuticals 37
Elanco Animal Health 37
Pharmaceuticals business unit structure 38

Chapter 5 Company sales 39

Key findings 39
Prescription pharmaceutical sales and growth rate analysis, 2002-14 40
Product analysis 42
Product analysis, 2002-08 43
Product analysis, 2008-14 45
Therapy area analysis 49
Geographic analysis 53
Launch/core/expiry analysis 55
Explanation of launch/core/expiry analysis 55
Launch analysis, 2008-14 56
Core analysis, 2008-14 60
Expiry analysis, 2008-14 62
Launch/core/expiry configuration, 2008-14 64
Molecule type analysis 65
Externalization analysis 67

Chapter 6 Company financials 69

Key findings 69
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 70
Operating costs and profit analysis 72
Operating costs and profit analysis, 2002-08 73
Operating cost ratio and profit margin analysis, 2002-08 74
Operating cost ratio and profit margin analysis, 2008-14 76
Operating costs and profit analysis, 2008-14 77

Chapter 7 Key products and competitors 79

Key findings 79
Overview 80
Central nervous system 81
Zyprexa 81
Overview 81
Sales forecast 82
Sales have slipped due to side effect concerns 82
Further gradual decline before US generics in 2011 82
Zypadhera delayed by side effect issues 83
Cymbalta 84
Overview 84
Sales forecast 85
Commercial success despite competition from Effexor and generic selective serotonin reuptake inhibitors (SSRI) 85
New indications have significantly lifted sales 85
Key growth driver to turn to decline in 2013 86
Endocrine, metabolic & genetic disorders 87
Byetta franchise 87
Overview 87
Sales forecast 88
First integrin mimetic to market 88
Competition challenges sales growth 89
Byetta LAR offers once-weekly convenience 89
Humalog franchise 90
Overview 90
Sales forecast 91
Insulin is the cornerstone of diabetes treatment 91
New Humalog formulations have driven further market expansion 91
Market leading position lost to new entrants 91
Scope for further growth is limited 92

Chapter 8 Appendix 94

R&D pipeline 94
Collaboration/ other revenue reconciliation 97
2002-08 97
2008-14 98
References 98
Abbreviations 99
Exchange rates 100
About Datamonitor 101
About Datamonitor Healthcare 101
Datamonitor consulting 101
Disclaimer 103

List of Tables

Table 1: Eli Lilly - PharmaVitae forecasts at a glance 8
Table 2: Eli Lilly key product developments, Q1-Q2 2009 26
Table 3: Eli Lilly product deals and alliances, Q1-Q2 2009 27
Table 4: Eli Lilly technology deals and alliances, Q1-Q2 2009 27
Table 5: Eli Lilly M&A activity, Q1-Q2 2009 27
Table 6: Eli Lilly company announcements, Q1-Q2 2009 28
Table 7: Eli Lilly future product milestones, 2009-11 29
Table 8: Eli Lilly product portfolio overview ($m), 2002-08 43
Table 9: Eli Lilly product portfolio overview ($m), 2008-14 45
Table 10: Eli Lilly prescription pharmaceutical sales by therapy area ($m), 2008-14 52
Table 11: Eli Lilly prescription pharmaceutical sales by geographic region ($m), 2008-14 54
Table 12: Eli Lilly launch portfolio overview ($m), 2008-14 56
Table 13: Eli Lilly core portfolio overview ($m), 2008-14 60
Table 14: Eli Lilly expiry portfolio overview ($m), 2008-14 62
Table 15: Eli Lilly prescription pharmaceutical sales by molecule type ($m), 2008-14 66
Table 16: Eli Lilly prescription pharmaceutical sales by source ($m), 2008-14 68
Table 17: Total Eli Lilly sales by business unit ($m), 2002-08 70
Table 18: Eli Lilly operating revenue/cost analysis ($m), 2002-08 73
Table 19: Eli Lilly operating cost ratio analysis (% of total revenues), 2002-08 74
Table 20: Eli Lilly operating cost ratio analysis (% of total revenues), 2008-14 76
Table 21: Eli Lilly operating revenue/cost analysis ($m), 2008-14 77
Table 22: Key products overview 80
Table 23: Zyprexa: overview 81
Table 24: Zyprexa: sales forecast ($m), 2008-14 82
Table 25: Cymbalta: overview 84
Table 26: Cymbalta: sales forecast ($m), 2008-14 85
Table 27: Byetta: overview 87
Table 28: Byetta franchise: sales forecast ($m), 2008-14 88
Table 29: Humalog franchise: overview 90
Table 30: Humalog franchise: sales forecast ($m), 2008-14 91
Table 31: Eli Lilly's R&D pipeline (Phase I-registration) 94
Table 32: Total Eli Lilly sales by business unit ($m), 2002-08 97
Table 33: Total Eli Lilly sales by business unit ($m), 2008-14 98
Table 34: Exchange rates, 2009 100

List of Figures

Figure 1: The PharmaVitae Explorer 3
Figure 2: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Eli Lilly's financial performance ($m), 2002-14 7
Figure 4: Impact of 'Year XYZ' expiries on Eli Lilly's total pharmaceutical sales 9
Figure 5: Eli Lilly year-on-year pharmaceutical revenue growth split by source, 2008-14 11
Figure 6: Sensitivity of Eli Lilly's pharmaceutical revenue outlook on key assumptions 13
Figure 7: Eli Lilly SWOT analysis 16
Figure 8: M&A/divestment history 32
Figure 9: Current corporate structure 36
Figure 10: Current corporate structure 36
Figure 11: Pharmaceuticals business unit structure 38
Figure 12: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 40
Figure 13: Key product sales ($m), 2002-14 42
Figure 14: Eli Lilly key sales growth drivers and resistors ($m), 2002-08 44
Figure 15: Eli Lilly key sales growth drivers and resistors ($m), 2008-14 47
Figure 16: Eli Lilly prescription pharmaceutical sales by therapy area ($m), 2002-14 49
Figure 17: Eli Lilly prescription pharmaceutical sales by geographic region ($m), 2002-14 53
Figure 18: Eli Lilly launch/core/expiry configuration ($m), 2008-14 64
Figure 19: Eli Lilly prescription pharmaceutical sales by molecule type ($m), 2002-14 65
Figure 20: Eli Lilly prescription pharmaceutical sales by source ($m), 2002-14 67
Figure 21: Eli Lilly operating revenue/cost analysis ($m), 2002-14 72

ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html

Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html

Browse all Newly Published Market Research Reports

Related Reports:

Eli Lilly & Co-Deals & Alliances Report
http://www.reportsandreports.com/reports/31388-eli-lilly-co-deals-alliances-report.html

Eli Lilly & Co-Detailed Product Pipeline
http://www.reportsandreports.com/reports/3894-eli-lilly-co-detailed-product-pipeline.html

Eli Lilly & Co.-Deals & Alliances Report
http://www.reportsandreports.com/reports/4349-eli-lilly-co-deals-alliances-report.html

Eli Lilly & Co-Therapeutic Competitors
http://www.reportsandreports.com/reports/3460-eli-lilly-co-therapeutic-competitors.html

Eli Lilly and Company Market Share Analysis
http://www.reportsandreports.com/reports/15576-eli-lilly-and-company-market-share-analysis.html

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

This release was published on openPR.